|
1
|
Palmieri TL, Przkora R, Meyer WJ III and
Carrougher GJ: Measuring burn injury outcomes. Surg Clin North Am.
94:909–916. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Spanholtz TA, Theodorou P, Amini P and
Spilker G: Severe burn injuries: Acute and long-term treatment.
Dtsch Arztebl Int. 106:607–613. 2009.PubMed/NCBI
|
|
3
|
Al-Mousawi AM, Mecott-Rivera GA, Jeschke
MG and Herndon DN: Burn teams and burn centers: The importance of a
comprehensive team approach to burn care. Clin Plast Surg.
36:547–554. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Williams FN, Herndon DN and Jeschke MG:
The hypermetabolic response to burn injury and interventions to
modify this response. Clin Plast Surg. 36:583–596. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Atiyeh BS, Gunn SW and Dibo SA:
Nutritional and pharmacological modulation of the metabolic
response of severely burned patients: Review of the literature
(Part II)*. Ann Burns Fire Disasters. 21:119–123. 2008.PubMed/NCBI
|
|
6
|
Rojas Y, Finnerty CC, Radhakrishnan RS and
Herndon DN: Burns: An update on current pharmacotherapy. Expert
Opin Pharmacother. 13:2485–2494. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Blizzard RM: History of growth hormone
therapy. Indian J Pediatr. 79:87–91. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hwang IT: Efficacy and safety of growth
hormone treatment for children born small for gestational age.
Korean J Pediatr. 57:379–383. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Fukuda I, Hizuka N, Muraoka T and Ichihara
A: Adult growth hormone deficiency: Current concepts. Neurol Med
Chir (Tokyo). 54:599–605. 2014. View Article : Google Scholar
|
|
10
|
Arce VM, Devesa P and Devesa J: Role of
growth hormone (GH) in the treatment on neural diseases: From
neuroprotection to neural repair. Neurosci Res. 76:179–186. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kemp SF and Frindik JP: Emerging options
in growth hormone therapy: An update. Drug Des Devel Ther.
5:411–419. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chen GX and Han CM: Influence of
recombinant human growth hormone on the prognosis of patients with
severe burns a prospective multi-center clinical trial. Zhonghua
Shao Shang Za Zhi. 21(347): 92005.(In Chinese). PubMed/NCBI
|
|
13
|
Breederveld RS and Tuinebreijer WE:
Recombinant human growth hormone for treating burns and donor
sites. Cochrane Database Syst Rev. 15:CD0089902012.
|
|
14
|
Liedert B, Forssmann U, Wolna P, Golob M
and Kovar A: Comparison of the pharmacokinetics, safety and
tolerability of two concentrations of a new liquid recombinant
human growth hormone formulation versus the freeze-dried
formulation. BMC Clin Pharmacol. 10:142010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Fuhr U, Tuculanu D, Berghout A, Balser S,
Schwebig A and Saenger P: Bioequivalence between novel ready-to-use
liquid formulations of the recombinant human GH Omnitrope and the
original lyophilized formulations for reconstitution of Omnitrope
and Genotropin. Eur J Endocrinol. 162:1051–1058. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wiesbauer J, Prassl R and Nidetzky B:
Renewal of the air-water interface as a critical system parameter
of protein stability: Aggregation of the human growth hormone and
its prevention by surface-active compounds. Langmuir.
29:15240–15250. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Iyoda K, Moriwake T, Seino Y and Niimi H:
The clinical usefulness of liquid human growth hormone (hGH)
(Norditropin SimpleXx in the treatment of GH deficiency. Horm Res.
51(Suppl 3): S113–S115. 1999. View Article : Google Scholar
|
|
18
|
Rousseau AF, Losser MR, Ichai C and Berger
MM: ESPEN endorsed recommendations: Nutritional therapy in major
burns. Clin Nutr. 32:497–502. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Jie W and Wang S: A nutritional formula
suitable for adults' burns in China. Chinese Journal of Surgery.
5:262–266. 1992.
|
|
20
|
Gauglitz GG, Williams FN, Herndon DN and
Jeschke MG: Burns: Where are we standing with propranolol,
oxandrolone, recombinant human growth hormone, and the new incretin
analogues? Curr Opin Clin Nutr Metab Care. 14:176–181. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Herndon DN, Barrow RE, Kunkel KR,
Broemeling L and Rutan RL: Effects of recombinant human growth
hormone on donor-site healing in severely burned children. Ann
Surg. 212:424–429; discussion 430–421. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Cynober L: Laboratory measurements in
clinical nutrition. In: Basics in clinical nutrition (4th edition).
Sobotka L (eds) and Wei C (translator). Shanghai Jiaotong
University Press. (Shanghai). 398–402. 2013.(In Chinese).
|
|
23
|
Branski LK, Herndon DN, Barrow RE, Kulp
GA, Klein GL, Suman OE, Przkora R, Meyer W III, Huang T, Lee JO, et
al: Randomized controlled trial to determine the efficacy of
long-term growth hormone treatment in severely burned children. Ann
Surg. 250:514–523. 2009.PubMed/NCBI
|
|
24
|
Przkora R, Herndon DN, Suman OE, Jeschke
MG, Meyer WJ, Chinkes DL, Mlcak RP, Huang T and Barrow RE:
Beneficial effects of extended growth hormone treatment after
hospital discharge in pediatric burn patients. Ann Surg.
243:796–801; discussion 801–793. 2006. View Article : Google Scholar : PubMed/NCBI
|
